**ROLE SUMMARY**

VELSIPITY represents an exciting growth opportunity that is integral to the performance of Pfizer Specialty Care. The launch of VELSIPITY in October 2023 was an important milestone as Pfizer endeavored to expand its leadership in I&I. This product could significantly change the early advanced therapy landscape with its unique balance of efficacy, favorable safety profile with no black box warning, and oral administration with no dose titration. Given the robust product profile, our history in the GI therapeutic area, and the substantial unmet need in UC, we project this product to become a significant revenue contributor within the Specialty Care portfolio. Now in its second year on-market in the US, VELSIPITY is poised for rapid growth that delivers both for Pfizer Specialty Care, as well as for the many patients in need of an effective oral treatment option in the first line of advanced therapy. VELSIPITY is at an extremely exciting juncture, having substant...